| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,790 | 0,825 | 06.02. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SPECTRAL MEDICAL Aktie jetzt für 0€ handeln | |||||
| 07.11.25 | Spectral Medical GAAP EPS of -$0.11, revenue of $0.6M | 1 | Seeking Alpha | ||
| 07.11.25 | Spectral Medical Inc.: Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update | 157 | GlobeNewswire (Europe) | PMA submission targeted for Q1 2026 following positive Tigris results and ongoing FDA interactionsCompany to host Corporate Update call on Wednesday, December 10, 2025 TORONTO, Nov. 07, 2025 (GLOBE... ► Artikel lesen | |
| 30.09.25 | Spectral Medical Inc: Spectral Medical files base shelf prospectus | 2 | Stockwatch | ||
| 29.09.25 | Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF | 1 | GlobeNewswire (USA) | ||
| 16.09.25 | Spectral Medical Inc: Spectral study defines deadliest septic shock group | 1 | Stockwatch | ||
| 16.09.25 | Spectral Medical Inc.: Spectral Medical Announces Publication of EDEN Observational Study | 8 | GlobeNewswire (USA) | ||
| 26.08.25 | Spectral Medical is a stock to buy now, this analyst says | 4 | Cantech Letter | ||
| 25.08.25 | Spectral Medical Inc: Spectral receives $3M (U.S.) tranche from Vantive | 2 | Stockwatch | ||
| 25.08.25 | Stocks in Play: Spectral Medical Inc. | 2 | Baystreet.ca | ||
| 25.08.25 | Spectral Medical Inc.: Spectral Medical Receives US$3 Million From Vantive | 360 | GlobeNewswire (Europe) | TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock... ► Artikel lesen | |
| 13.08.25 | XFRA SD4: WIEDERAUFNAHME/RESUMPTION | 372 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 13.08.25 | XFRA SD4: AUSSETZUNG/SUSPENSION | 223 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSPECTRAL MEDICAL... ► Artikel lesen | |
| 13.08.25 | Spectral Medical Inc: Spectral's PMX reduces mortality in septic shock trial | 4 | Stockwatch | ||
| 12.08.25 | Spectral Medical Inc.: Spectral Medical and Vantive Announce Topline Results from Spectral's Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock | 224 | GlobeNewswire (Europe) | Results exceed prespecified primary endpoint of 95% posterior probability of benefit for PMX on 28-day mortality Pooled absolute risk reduction of 8.3%; Relative risk reduction of 18% Key secondary... ► Artikel lesen | |
| 08.08.25 | Spectral Medical Inc.: Spectral Medical Announces Second Quarter and Provides Corporate Update | 242 | GlobeNewswire (Europe) | Topline Tigris results expected to be released around mid-August 2025 TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic... ► Artikel lesen | |
| 06.06.25 | Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders | 182 | GlobeNewswire (Europe) | TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock... ► Artikel lesen | |
| 09.05.25 | Spectral Medical Inc.: Spectral Medical Announces First Quarter and Provides Corporate Update | 261 | GlobeNewswire (Europe) | Tigris Trial Enrollment completedTopline results expected to be released in August 2025Entered into an up to US$10 million Promissory Note with Vantive to Fund Spectral to PMX commercialization ... ► Artikel lesen | |
| 07.05.25 | Spectral Medical Inc.: Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive | 333 | GlobeNewswire (Europe) | • Non-Dilutive Financing • Up to US$10 Million Promissory Note Provided by Vantive • If Fully Drawn, Promissory Note is Expected to Fully Fund Spectral to PMX Commercialization • Company to... ► Artikel lesen | |
| 16.04.25 | Spectral Medical Inc.: Spectral Medical Completes Tigris Trial Enrollment | 265 | GlobeNewswire (Europe) | 157 patients enrolledTopline results expected to be released in August 2025Company to host Corporate Update Call on May 15, 2025 TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc.... ► Artikel lesen | |
| 27.03.25 | Spectral Medical Inc.: Spectral Medical Announces Fourth Quarter and Fiscal 2024 Results and Provides Corporate Update | 367 | GlobeNewswire (Europe) | TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 40,640 | +0,40 % | DAX-Check LIVE: Fresenius Medical Care, Nordex, Puma, Sartorius Vz., Schaeffler, Siltronic im Fokus | Ein kurzzeitiger Ausverkauf bei Gold und Silber hat den DAX zum Wochenstart zunächst belastet. Die Unsicherheit beruhigte sich jedoch im Tagesverlauf, auch unterstützt durch eine Erholung an den US-Märkten.... ► Artikel lesen | |
| RHOEN-KLINIKUM | 13,200 | +1,54 % | EQS-Adhoc: RHÖN-KLINIKUM Aktiengesellschaft: RHÖN-KLINIKUM passt die EBITDA-Prognose für das Geschäftsjahr 2025 an | EQS-Ad-hoc: RHÖN-KLINIKUM Aktiengesellschaft / Schlagwort(e): Prognoseänderung
RHÖN-KLINIKUM Aktiengesellschaft passt die EBITDA-Prognose für das Geschäftsjahr 2025 an... ► Artikel lesen | |
| ROKU | 73,07 | +0,63 % | This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday | ||
| SERNOVA BIOTHERAPEUTICS | 0,086 | -7,53 % | Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 13, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH) ("Sernova or the Company)") a leading regenerative medicine... ► Artikel lesen | |
| FAMICORD | 5,400 | 0,00 % | EQS-News: FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung | EQS-News: FamiCord AG
/ Schlagwort(e): 9-Monatszahlen
FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung... ► Artikel lesen | |
| M1 KLINIKEN | 17,100 | +3,01 % | EQS-News: M1 Kliniken AG: Abschluss des Verkaufs der 100 %-Tochtergesellschaft HAEMATO Pharm GmbH an PHOENIX group | EQS-News: M1 Kliniken AG
/ Schlagwort(e): Verkauf/Beteiligung/Unternehmensbeteiligung
M1 Kliniken AG: Abschluss des Verkaufs der 100 %-Tochtergesellschaft HAEMATO Pharm GmbH an... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,670 | -2,20 % | GERATHERM MEDICAL AG - Schwäche im aktuellen Marktumfeld | ||
| PLUS THERAPEUTICS | 0,256 | +10,65 % | Plus Therapeutics Inc.: Plus Therapeutics Provides Business Update on REYOBIQ Clinical Program and U.S. CNSide Commercialization | HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 41,400 | -2,82 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers mit einem Kursziel von 60 Euro auf "Buy" belassen. Der Aktienkurs der Münchner spiegle die mittelfristigen... ► Artikel lesen | |
| FRESENIUS | 49,760 | +1,06 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius mit einem Kursziel von 55 Euro auf "Buy" belassen. Die Bad Homburger seien in Verjüngungskur, und der Markt preise... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 28,740 | +4,89 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,680 | +3,44 % | BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 | ||
| CARL ZEISS MEDITEC | 27,520 | +0,66 % | BARCLAYS stuft CARL ZEISS MEDITEC AG auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 49 auf 32 Euro gesenkt und die Aktien von "Overweight" auf "Equal Weight" abgestuft. Nur... ► Artikel lesen | |
| HEARTFLOW | 27,690 | +6,54 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| GENEDX | 84,35 | +0,32 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen |